Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Bispecific Antibodies in Oncology Market $19.6 Billion by 2029

The global market for bispecific antibodies in oncology projected to reach $19.6 billion by 2029, expanding at a double-digit CAGR of 24.3% over the forecast period, driven by increasing prevalence of hematological malignancies, lung cancer, and eye disorders, as well as rich pipeline of potential candidates.

  • Major applications of bispecific antibodies (bsAbs) are T cell redirection, dual targeting of disease mediators, half-life extension, and delivery across membranes. T cell redirection for oncology is the most prominent application of bsAbs accounting for about half of the clinical stage bsAbs.
    • Dual targeting, either blocks two disease mediators or brings together biologically functional proteins.
    • Half-life extension takes advantage of the longer half-life of serum albumin, especially useful in applications such as enhanced tumor penetration and subcutaneous delivery.
    • The delivery across the blood brain barrier targeting in the brain or cargo delivery (such as enzymes) can be achieved.
Global Bispecific Antibodies in Oncology Market

Bispecific antibodies are a diverse family of antibodies or antibody constructs that recognize two epitopes or antigens. Most bsAbs are bispecific T-cell-engagers (BiTEs), designed to redirect and/or activate CD3-expressing cytotoxic T cells (CTLs) against a specific tumor target on malignant cells. Other bsAb classes include therapies that target immune checkpoints, oncogenic signaling pathways and cytokines. Bifunctional fusion proteins are a subset of bsAbs that are typically devoid of an Fc region.

  • With four bispecific antibodies on the market, this modality is increasingly making its way through many biotech and pharma pipelines that want to target novel multifactorial biology by engaging two antigens or two epitopes on the same antigen. Discovery and development of these potent therapeutics is challenging and requires several folds of effort to optimize multiple variables than conventional antibodies.

All four marketed bispecific drugs target different biology, i.e., T cell redirection (blinatumomab), cofactor mimicking by bringing together two coagulation factors (emicizumab) and dual targeting (amivantamab and faricimab). The field is currently primed for several new approvals in oncology (KN046, glofitamab, epcoritamab, and mosunetuzumab).

  • Blincyto (blinatumomab) is used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. In 2018, the US FDA granted accelerated approval to blinatumomab for the treatment of adult and pediatric patients with B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
    • Blincyto can also be used in patients who are ‘Philadelphia-chromosome-positive’ (Ph-positive) if their cancer has not responded to previous treatment with at least two medicines called tyrosine kinase inhibitors and they have no alternative treatment options.
  • Hemlibra (emicizumab) is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.
    • In 2018, the US FDA approved emicizumab injection for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.
  • Rybrevant (amivantamab) is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal-epithelial transition (MET) receptor-directed antibody medication used to treat non-small cell lung cancer.
    • It is the first treatment approved by the US FDA in 2021 for adults with non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
  • Vabsymo (faricimab)] is used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor.
    • By targeting these pathways, faricimab stabilizes blood vessels in the retina. Faricimab completed Phase III trials and was approved for medical use in the United States in 2022.

The versatility of bispecific antibodies introduces a wide range of potential applications.

  • bsAbs can be designed for multiple targeted approaches:
    • Two epitopes on a single cancer target1
    • Two distinct antigens on the same tumor cell
    • Two antigens on different cells within the tumor microenvironment
  • bsAbs can direct protein-protein interactions by targeting different proteins on the same cell.
    • This allows for more efficient modification of cell signaling, potentially resulting in the deactivation of proliferation or inflammatory pathways.
  • They can also direct cell action in a specific setting by addressing two targets on different cell types.
    • This allows for mediating the redirection of immune effector cells, such as NK cells and T cells, to tumor cells in order to potentially enhance tumor destruction.

The global market for bispecific antibodies in oncology research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).

The global market for bispecific antibodies in oncology segmented by product [Blincyto (blinatumomab), Hemlibra (emicizumab), Rybrevant (amivantamab), Vabsymo (faricimab)], pipeline analysis (Elranatamab, Epcoritamab, Erfonrilimab, Glofitamab, KN046, Mosunetuzumab, Tebentafusp, Tebotelimab, Teclistamab, Zanidatamab), and geography.

  • Based on the marketed products, Hemlibra (emicizumab) segment accounted for the largest share of the total market, whereas the Rybrevant (amivantamab) segment anticipated to witness the fastest double-digit growth rate in the coming years.
  • The Vabsymo (faricimab) segment accounted for the second largest share of the total market, as well as the second fastest CAGR during the forecast period.
  • The global market for the products in the late-stage development accounted for about 20% of the total marketed bispecific antibodies in the cancer market.

The global market for bispecific antibodies in cancer research report further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for bispecific antibodies in oncology report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global market for bispecific antibodies in cancer and profiled in this report include Alphamab Oncology, Amgen, Inc., Chugai Pharmaceutical Co., Ltd., Genmab A/S, Immunocore, Johnson & Johnson (Janssen), MacroGenics, Inc., Pfizer, Inc., Roche Holding AG, and Zymeworks, Inc.

  • Product
    • Blincyto (Blinatumomab)
    • Hemlibra (Emicizumab)
    • Rybrevant (Amivantamab) 
    • Vabsymo (Faricimab)
  • Pipeline Analysis
    • Elranatamab
    • Epcoritamab
    • Erfonrilimab
    • Glofitamab
    • KN046
    • Mosunetuzumab
    • Tebentafusp
    • Tebotelimab
    • Teclistamab
    • Zanidatamab
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Alphamab Oncology
    • Amgen, Inc.
    • Chugai Pharmaceutical Co., Ltd.
    • Genmab A/S
    • Immunocore
    • Johnson & Johnson (Janssen)
    • MacroGenics, Inc.
    • Pfizer, Inc.
    • Roche Holding AG
    • Zymeworks, Inc.

To request Table of Contents and Sample Pages of this report https://www.ihealthcareanalyst.com/report/bispecific-antibodies-oncology-market/

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com